ERBB2 and breast cancer: The ORR and DCR were 36% (4/11) and 64% (7/11) in 11 TRD patients with TNBC, respectively, while 62% (8/13) and 77%/ (10/13) in 13 TRD patients with HR+/HER2-breast cancer.